Top Banner
The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN
84
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

The Child With a Malignancy

Jan Bazner-ChandlerCPNP,MSN, CNS, RN

Page 2: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Developmental and Biologic Variances Most childhood cancers arise for embryonic

mesodermal germ layer Involves tissues of:

CNS, bone, muscle, endothelial tissue, connective tissue, blood, lymph tissue

Grows in a short period of time 80% have metastasis at time of diagnosis

Page 3: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Assessment Unusual mass or swelling Unexplained paleness and loss of energy Spontaneous bruising Prolonged, unexplained fever Headaches in morning Sudden eye or vision changes Excessive – rapid weight loss

Page 4: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Diagnostic Tests X-ray Skeletal survey CT scan Ultrasound MRI Bone marrow aspiration CBC with absolute neutrophil count Urinalysis Lumbar puncture Urine catecholamines

Page 5: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Treatment Modalities Determined by:

Type of cancer

Location

Extent of disease

Page 6: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Surgical Management The oldest form of cancer treatment Surgery plays important role in initial

diagnosis: biopsy of primary tumor. Excision of tumor when possible Facilitating treatment: insertion of catheters

for long-term treatment

Page 7: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Radiation Therapy The use of ionizing radiation to break apart

bonds within a cell causing cell damage and death.

External beam therapy accounts for the majority of radiation treatments in children.

Problems: radiation beams cannot distinguish between malignant cells and healthy cells.

Page 8: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Chemotherapy Primary treatment modality used to cure

many pediatric cancers. Chemotherapy is the use of drugs to destroy

cancer cells. The destruction is accomplished by inhibiting

cells within the body to divide, which eventually leads to cell death.

Page 9: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Chemotherapy Can be given in addition to another form of

therapy such as radiation or surgery. Drugs may be administered before surgery to

reduce size of tumor. Adjuvant chemotherapy is used after surgery

or radiation therapy to prevent relapse.

Page 10: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Chemotherapy Combination chemotherapy is the use of more

than one class of drug. Administering different classes of chemo

drugs ensures a greater chance of achieving complete cancer cell destruction and achieving remission.

Page 11: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Administration Chemotherapy can be given by mouth,

subcutaneous or intramuscular injections, intravenously, or intrathecally. Oral route used if drug is well absorbed and non

irritating to the GI tract Sub-q or IM: Slow systemic release IV push, piggyback or intravenous infusion

Page 12: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Goals of Chemotherapy Reducing the primary tumor size Destroying cancer cells Preventing metastases and microscopic

spread of the disease

Page 13: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Chemotherapy Drugs Alkylating drug: attack DNA Antimetabolites: interfere with DNA

production Antitumor antibiotics: interferes with DNA

production Plant alkaloids: prevent cells from dividing Steroid hormones: slow growth of some

cancers

Page 14: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Bone Marrow Transplant HSCT: Hematopoietic Stem Cell Transplant:

CHLA has one of the largest program. The option of HSCT depends on the patients

disease, disease status, and general physical condition.

Involves: Umbilical cord blood Parent’s stem cells

Page 15: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Gene Therapy Use of gene therapy in the treatment of

childhood cancer is promising yet complex and still in early phases of clinical application.

Page 16: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Management Patient / family education

Begins at time of diagnosis Continues through treatment phases Maintained in post-survival years Support if death of child

Page 17: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Pain Management Pain caused by disease

Pain with procedures and treatments

Pain associated with side effects of treatment

Page 18: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Pain Management Pharmacologic

Non-Pharmacologic

Sedation or anesthetic medications EMLA cream Conscious sedation

Page 19: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Pain Control

Page 20: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Immunosuppression and Infection Children with cancer become immune impaired

from a number of causes: Lymphocyte production is altered Splenic dysfunction can prevent maturation of blood

cells and alteration is inflammatory response. Cancer therapy can decrease immunoglobulin

concentrations.

Page 21: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Neutropenia Significant neutropenia can develop during

chemotherapy creating an increased risk of infection in the child with cancer.

Neutropenia occurs when the absolute neutrophil count decreases below 500.

Page 22: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Treatment for Neutropenia Granulocyte colony stimulating factor

decreases the duration of neutropenia by stimulating the proliferation of the progenitor cells of the granulocytes, specifically the neutophils.

G-CSF: 5mcg/kg/day given subcutaneous

Page 23: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Varicella If an immunosuppressed child with no history

of varicella infection or varicella immunization has direct contact with an individual with chickenpox or shingles, varicella zoster immune globulin should be administered.

Acyclovir IV is used in some cases.

Page 24: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Varicella Immunizations Three months after chemotherapy Off prednisone Many will have already had the immunization

as a toddler since it is now a required immunization.

Page 25: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Central Venous Access Devices Two decades ago, CVAD were introduced as

an integral part of the pediatric oncology patient’s treatment plan.

Used to deliver chemotherapy, blood components, antibiotics, fluids, TPN, medications and blood sampling.

Page 26: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

CVAD Infection Prevention• Teach family to report signs of catheter

infections: fever, chills, swelling, pain, drainage, or erythema.

• Aseptic technique for dressing changes and heparin flushing.

• Avoid trauma to device• Observe for catheter occlusion

Page 27: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Chemotherapy Side Effect Drugs affect not only the cancer cells but also

healthy cells. Cells most affected are rapidly growing cells

such as hair follicles, reproductive system, bone marrow and gastrointestinal tract.

Page 28: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Management of Side Effects

Page 29: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Malnutrition Occurs in 8 to 32% of the pediatric oncology

population Nutritional goals focus on maintaining normal

growth and development as well as preventing nutritional deficiencies.

Page 30: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Nutrition Interventions Initial nutritional assessment History of child’s eating habits, food allergies,

use of nutritional supplements, base line weight and height measurements.

Enteral feedings at night: preserve intestinal mucosa by keeping it functional

Page 31: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Nausea and Vomiting Most common side effect of cancer treatment. Chemotherapy-associated vomiting is a reflex

controlled by chemoreceptor trigger zone that stimulates the vomiting center in the brain.

Tumor location Radiation therapy Anticipatory nausea

Page 32: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Interventions Antiemetics such as Phenothiazines:

(Trilafon), (Phenergan)and (Thorazine) block dopamine receptors from stimulating the chemoreceptor trigger zones.

Serotonin-receptor antagonist such as Granisetron (Kytril) and Ondansetron (Zofran) are very effective. (>3 years)

Antihistamines: benadryl Administer before chemotherapy

Page 33: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Mucositis Progressive, inflammatory, ulcerative condition of

the oral and gastric mucosa. Occurs due to the interruption of cell renewal

process of the epithelium leading the mucosal atrophy and ulceration

Thrombocytopenia or physical trauma may lead to bleeding and further mucosal damage.

Neutropenia and poor dental hygiene predisposes the oral mucosa to secondary infection.

Page 34: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Assessment / Interventions Baseline assessment including the oral cavity,

teeth, and gingival mucosa. History of dental exam and use of orthodontic

appliances Meticulous oral care Mouth rinses Monitor hydration status

Page 35: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Constipation Assess normal bowel habits Increase fiber and fluids in diet Stool softeners / colace Physical activity Avoid digital manipulation

Page 36: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Diarrhea Assess for signs of dehydration Record stool patterns IV fluids as needed Low-residue or lactose-free diet Good hand washing

Page 37: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Hair Loss More important in the older child. Most patients will experience hair loss within

10 days of induction chemotherapy Prepare patient for hair loss Males: shave hair Females: short hair style – pick out wig – scarf

- hat

Page 38: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Psychosocial Support Support groups

Open communication

Daily contact with oncology team

Trusting relationship with nurse

Page 39: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Growth and Development Promote normal G & D Allow decision making Establish daily routines Play therapy Friends School attendance or tutor

Page 40: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Late Effects of Cancer Therapy Endocrine: sterility Thyroid Cardiovascular Musculoskeletal Vision Hearing Respiratory Gastrointestinal Genitourinary Hematopoietic

Page 41: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Leukemia Most common malignancy Cancer of blood or bone marrow characterized

by an abnormal proliferation of blood cells, usually white blood cells (leukocytes)

Two types Acute lymphoblastic leukemia: 78% Acute Myelogenous leukemia: 15 to 20%

High survival rate

Page 42: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Prognosis Initial WBC most significant The higher the count the poorer the outcomes

Greater than 100,000 WBC count = poor outcome Children under 2 years and older than 10 Girls do better than boys

Page 43: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Diagnosis Peripheral blood smear

Bone marrow analysis

Lumbar puncture

Page 44: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Assessment Pallor and fever Lethargy Anorexia Weight loss Hemorrhage / petechiae Hepatomegly / splenomegaly

Page 45: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

3 Phase Treatment Induction: goal is to achieve remission last

about a month Consolidation: most intensive phase of

chemotherapy lasts 4 to 8 months Maintenance: last two to three years If leukemia cells are detected in bone marrow

process is started all over again.

Page 46: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Induction Therapy Goal of therapy is to achieve remission Leukemia cells are no longer found in the

bone marrow samples, the normal cells return and blood counts become normal.

Drugs used: L-asparaginase, vincristine and a steroid (dexamethasone), for high-risk children a fourth drug (daunorbucin) is often used

Page 47: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Consolidation Phase Several drugs are used in combination to

prevent remaining leukemia cells from developing resistance.

Drugs include: methotrexate and 6-mercaptopurine, vincristine and prednisone

Page 48: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Maintenance If leukemia continues to be in remission

maintenance therapy can be started. Two drugs: vincristine and steroids over a

brief period every 4 to 8 weeks. Duration of total therapy 2 to 3 years.

Page 49: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

CNS Therapy CNS prophylaxis is initiated at diagnosis and is

used to reduce the risk for CNS disease. Preventive CNS is based on the premise that

the CNS provides a sanctuary site for leukemic cells that are undetected at diagnosis and reside protected from the action of systemic therapy by the brain blood barrier.

Page 50: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Multidisciplinary Interventions Assess for infection Monitor blood values I & O / nutrition Complications of chemotherapy Good hand washing Aseptic technique for blood draws

Page 51: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Leukemia Time Line 1962 cure rate for pediatric cancer is 4 %. 1971 – A combination of chemotherapy and

cranial irradiation proves it can cure at least half of all children with ALL.

1975 – A new combination of chemo drugs helps patients with reocurrence of the disease.

1991 Long-term survival rate increases to 73% with intensive induction therapy followed by two years of treatment with eight anti cancer drugs used on a rotating basis

Page 52: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Time Line 1997 – Bone marrow transplants from

unrelated, genetically matched donors are effective against many childhood leukemia's.

1998 – survival rate 73% to 80%. 2004 – survival rate 85% 2006 – survival rate 94%

Page 53: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

CNS Tumors• 2nd most common malignancy• 65% have 5 year survival rate• Most common tumors:

• Astrocytomas 50%• Medulloblastomas 25%• Brain stem gliomas 10%

Page 54: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Assessment Classic signs and symptoms are indicative of

increased intracranial pressure. Pressure is due to tumor mass compressing

vital structure, blockage of cerebrospinal fluid flow or tumor associated edema. Gait changes / ataxia Headache with or without vomiting Blurred vision, or diplopia Forceful vomiting upon rising in the morning or

papilledema.

Page 55: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Multidisciplinary Interventions Surgery if tumor accessible Chemotherapy Radiation = Reserved for patient older that 2-

years of age Survival rate based on location

Page 56: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Chemotherapy After surgery to prevent tumor from coming

back Shrink tumor that cannot be operated on Shrink tumor so it can be operated on

Page 57: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Chemotherapy Blood brain barrier – natural filter within the

body that allows certain substances through from the blood to the brain tissues.

Drugs used are: temozolamide, procarbazine or lomustine

Methotrexate is injected intra-thecal Implantable wafers: drug is fixed with gel

wafer – drug is slowly released into brain over 2 to 3 weeks

Page 58: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Brain Tumors

Astrocytoma

Large right frontal lobe

neoplasm with small

area of necrosis

Page 59: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Hodgkin's Disease 3rd most common malignancy

15 to 30 years

Three times higher in males

Excellent cure rates

Page 60: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Assessment Night sweats

Weight loss

Malaise

Painless, firm nodes

Page 61: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Treatment Radiation to nodes Chemotherapy

Combination therapy for six months Prednisone

Stem cell transplant

Page 62: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Neuroblastoma Approximately 600 new cases a year. Embryonic tumor Average age of diagnosis is 2 years. Poorest survival rate 50 to 60% have metastases at time of

diagnosis.

Page 63: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Assessment Depends on site of tumor

Diagnosis CT scan Bone scan 95% secrete catecholamines in the urine.

Page 64: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Multidisciplinary Interventions Determined by the stage of disease and age

of child. Children who have localized disease and

complete response to treatment are more likely to achieve a disease free state and long-term survival.

Page 65: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Neuroblastoma

Page 66: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Wilm’s Tumor Most common type of renal tumor in children Approximately 460 new cases each year. Children with hypospadius or cryptorchidism

have a slightly higher incidence. African American and Females at highest risk

Page 67: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Assessment Firm non-tender, painless mass in abdomen

Hematuria

Hypertension

Do not palpate the abdomen

Page 68: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

CT Scan Wilm’s Tumor

Page 69: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Wilm’s Tumor

Page 70: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Multidisciplinary Interventions Surgery

Nephrectomy Prevent rupture of capsule Sample for pathology

Chemotherapy and radiation are given based on the stage of the disease.

Page 71: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Osteogenic Sarcoma Malignant tumor of bone

Peak incidence between ages 10 and 20 years

Genetic predisposition

Approximately 20% have metastases at diagnosis

High rate of metastasis to lungs

Page 72: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Assessment Pain in affected limb that increases with

activity or weight bearing Refusal to walk and limited range of motion Tenderness and edema Diagnosis often made after traumatic injury

Page 73: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Diagnosis

Page 74: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Multidisciplinary Interventions Limb salvage

Amputation

Chemotherapy

Page 75: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Limb Salvage

http://www.clevelandclinic.org/ortho/tumor/limbSalvageLg.htm

Page 76: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Ewing Sarcoma Tumor of flat bones

Pelvis, chest, vertebrae

Rare in children under 5 years

75% diagnosed by age 20

Page 77: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Ewing Sarcoma

Page 78: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Rhabdomyosarcoma Most common soft bone tissue tumor

Head and neck 40% GU 20% Extremities 20% Trunk 15%

Page 79: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Prognosis Location Extent of disease Children with no detectible metastases at

time of diagnosis have better outcomes Head and neck tumors have better prognosis 72% survival rate after 5 years

Page 80: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Multidisciplinary Interventions Biopsy of tumor mass Imaging studies Surgical removal Chemo based on tissue biopsy Radiation

Page 81: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Retinoblastoma Intraocular tumor composed of embryonal

retinal cells

1 in 16,000

+ family history

High incidence of malignancies

Page 82: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Assessment Child may initially present with strabismus Impaired vision Creamy white pupillary reflex Painful eyes from inflammation

Page 83: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Retinoblastoma

Pupil reflex

“Cat Eyes”

Page 84: The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN.

Multidisciplinary Interventions Surgical enucleation of eye

Genetic counseling

Follow-up care up to 18 Years